ABSTRACT
Equid alphaherpesvirus 3 (EHV3) is the etiological agent of equine coital exanthema (ECE), which is a venereal, highly contagious disease, characterized by the formation of papules, vesicles, pustules and ulcers on the external genitalia of mares and stallions. EHV3 remains in a latent state after a successful infection and there are latently infected animals in which the virus is reactivated and generally re-excreted subclinically. There are no available vaccines for this condition and prevention is based on the clinical examination of mares prior to mating, which allows to segregate those showing clinical signs. As this approach does not eliminate the risk of contagion in stallions from subclinically infected mares, there is a need for a specific EHV3 treatment. Nowadays, there exist various antiviral compounds of proven effectiveness for other alphaherpesviruses affecting humans and animals. The aim of the present study was to compare the efficacy of three antiviral compounds, acyclovir, ganciclovir and cidofovir against EHV3 in vitro, and to assess their efficacy against six EHV3 Argentinian field isolates. To determine the efficacy of these compounds in vitro, three parameters were analyzed: reduction of plaque number, reduction of plaque size and reduction of viral production. Additionally, the effectiveness of the three compounds at an optimum concentration previously determined in this study was investigated for the EHV3 field isolates. Based on our results, ganciclovir was the most potent antiviral compound to reduce EHV3 replication in vitro and may thus be a valuable candidate for treatment and prevention of ECE in mares and stallions.
El alfa-herpesvirus equino 3 (EHV3) es el agente etiológico del exantema coital equino (ECE), enfermedad venérea, altamente contagiosa y caracterizada por la aparición de pápulas, vesículas, pústulas y úlceras en los genitales externos de yeguas y padrillos. Luego de la primo-infección, el EHV3 se mantiene en el animal en un estado de latencia a partir del cual puede reactivar y excretarse, generalmente de manera subclínica. No existen vacunas, por lo que la prevención se basa en la detección de las lesiones clínicas previo al servicio, y la segregación de estos animales. Sin embargo, este abordaje no previene la infección del padrillo por parte de yeguas que excretan el virus de manera subclínica, y por lo tanto existe la necesidad de un tratamiento específico contra el EHV3. En la actualidad, existen varios compuestos antivirales de probada eficacia contra herpesvirus humanos y veterinarios. El objetivo de este trabajo es comparar la eficacia de 3 compuestos antivirales, aciclovir, ganciclovir y cidofovir, contra EHV3 in vitro, y evaluar la eficacia de los mismos contra 6 cepas de campo argentinas de EHV3. Para determinar la eficacia de los compuestos in vitro se evaluaron 3 parámetros: reducción del número de placas de lisis, reducción del tamaño de placas de lisis y reducción de la producción de virus. Adicionalmente, la efectividad de los compuestos en una concentración óptima, previamente determinada en este estudio, fue determinada para 6 cepas de campo argentinas de EHV3. De acuerdo con los resultados obtenidos, ganciclovir fue el compuesto más potente en reducir la replicación del EHV3 in vitro, y por lo tanto podría considerarse un potencial candidato para el tratamiento y la prevención del ECE en yeguas y padrillos.
Subject(s)
Animals , Female , Antiviral Agents/pharmacology , Acyclovir/pharmacology , Ganciclovir/pharmacology , Herpesvirus 3, Equid/drug effects , Herpesviridae Infections/veterinary , Cidofovir/pharmacology , Horse Diseases/virology , Cells, Cultured , Herpesvirus 3, Equid/isolation & purification , Herpesviridae Infections/virology , HorsesABSTRACT
This study evaluated the epizootiological characteristics of equine coital exanthema (ECE) in South Korea. A PCR test was used to determine the equine herpesvirus 3 (EHV-3) release period, excretion by suckling foals, morbidity rate, effect on fertility, and onset of breeding partner after treatment. The morbidity rate of ECE based on clinical symptoms was 8.3% (2/24) for stallions and 10.8% (45/416) for mares, and 29 of 45 (64.4%) animals were positive on the PCR test. Ten (22%) broodmares had symptoms before breeding, while 26 (58%) had symptoms after breeding. Nine (20%) mares had uncertain coverage periods and occurrence times. Suckling foals had no clinical findings and EHV-3 was not detected in their nostrils, although it was detected on teasers. No lesions were observed in the clitoral fossa on broodmares, although EHV-3 was detected by PCR. The period of EHV-3 emission was 22~23, 18~19, 6, and 58 days in stallions, broodmares, teasers, and mares with a mixed E. coli-like infection, respectively. ECE had no negative effects on the breeding capability of stallions and no symptoms were observed in broodmares after recovering from ECE.